Konstantin Adamsky
Director/Board Member at FILAMENT HEALTH CORP.
Konstantin Adamsky active positions
| Companies | Position | Start | End |
|---|---|---|---|
| FILAMENT HEALTH CORP. | Director/Board Member | 2022-08-22 | - |
| Independent Dir/Board Member | 2022-08-22 | - |
Career history of Konstantin Adamsky
Former positions of Konstantin Adamsky
| Companies | Position | Start | End |
|---|---|---|---|
Regenera Pharma Ltd.
 Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | Chief Executive Officer | 2013-02-28 | 2017-07-31 |
| Chief Operating Officer | 2017-07-31 | 2020-09-30 | |
| Levco Pharmaceuticals Ltd. | Chief Operating Officer | - | - |
Training of Konstantin Adamsky
| Weizmann Institute of Science | Doctorate Degree |
Statistics
International
| Israel | 4 |
| Canada | 2 |
Operational
| Chief Executive Officer | 3 |
| Director/Board Member | 3 |
| Chief Operating Officer | 2 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| FILAMENT HEALTH CORP. | Health Technology |
| Private companies | 2 |
|---|---|
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | Health Technology |
| Levco Pharmaceuticals Ltd. |
- Stock Market
- Insiders
- Konstantin Adamsky
- Experience
